MTHFR DNA Testing: Purpose and Interpretation
The MTHFR DNA test identifies genetic variants (polymorphisms) in the methylenetetrahydrofolate reductase gene that can impair folate metabolism and lead to elevated homocysteine levels, which may contribute to cardiovascular disease risk and other conditions.
What This Test Detects
The MTHFR DNA test screens for common genetic polymorphisms, primarily:
- C677T (rs1801133) - the most clinically significant variant 1, 2
- A1298C (rs1801131) - a secondary variant with milder effects 2
These variants affect the MTHFR enzyme's ability to convert folate into its active form (5-methyltetrahydrofolate), which is essential for converting homocysteine back to methionine 1.
What a "Positive" Result Means
A positive result indicates you carry one or both copies of these variants:
Heterozygous (One Copy)
- C677T heterozygous: Mildly reduced enzyme activity
- May contribute to elevated homocysteine, especially with low folate intake 3
Homozygous (Two Copies)
- C677T homozygous (TT genotype): Significantly reduced enzyme activity (up to 70% reduction)
- More likely to cause elevated homocysteine levels, particularly when folate status is marginal 3, 1
- The enzyme becomes heat-labile and functions poorly at body temperature 1
Compound Heterozygous
- Carrying both C677T and A1298C variants or C677T with rarer mutations can produce moderate to severe biochemical abnormalities 4
Clinical Significance
The polymorphism itself is NOT a disease - it's a common genetic variant found frequently in the general population 3. The key issue is whether it leads to elevated homocysteine levels.
When It Matters Clinically:
Elevated homocysteine (>15 μmol/L) is the actual risk factor, not the gene variant alone 3. The MTHFR polymorphism may contribute to elevated homocysteine when combined with:
- Poor dietary folate intake 3, 5
- Vitamin B12 or B6 deficiency 3
- Renal dysfunction 5
- Certain medications 3
Associated Conditions (when homocysteine is elevated):
- Cardiovascular disease: Homocysteine >15 μmol/L increases risk for premature vascular occlusion; levels of 10-15 μmol/L may confer graded risk 3
- Thrombotic events: Increased pro-thrombotic state 5
- Pregnancy complications: Recurrent pregnancy loss, pre-eclampsia, neural tube defects 2
- Neuropsychiatric conditions: Variable associations with depression, schizophrenia, autism 6, 2
Critical Pitfall to Avoid
Do not treat based on genetic testing alone 3. The MTHFR variant is meaningless without measuring actual homocysteine levels. Many people with the C677T polymorphism have normal homocysteine and require no intervention.
Appropriate Next Steps After a Positive Test
Measure fasting plasma total homocysteine - this is the critical determinant of clinical significance 3
If homocysteine is elevated (>15 μmol/L), also measure:
- Serum and erythrocyte folate
- Serum vitamin B12 (cobalamin)
- Serum/urine methylmalonic acid
- Renal function 3
If homocysteine is normal, no treatment is needed regardless of MTHFR genotype
Treatment Considerations (Only When Homocysteine is Elevated)
For C677T homozygotes with elevated homocysteine:
- 5-methyltetrahydrofolate (5-MTHF) 400-600 μg daily is preferred over folic acid because it bypasses the defective MTHFR enzyme 5, 7
- Standard folic acid (400 μg/day) typically reduces homocysteine by 25-30% 5
- Adding vitamin B12 (0.02-1 mg/day) provides an additional 7% reduction 5
Critical warning: Never supplement with folate alone without checking B12 status first, as this can mask B12 deficiency while allowing neurological damage to progress 3.
What This Test Does NOT Tell You
- It does not diagnose severe MTHFR deficiency (a rare inherited metabolic disorder requiring specialized testing) 8
- It does not predict cardiovascular disease risk independently 5, 1
- It does not indicate whether treatment will reduce cardiovascular events (clinical trials have been disappointing) 5
The bottom line: A positive MTHFR genetic test is only clinically actionable when accompanied by elevated homocysteine levels and appropriate vitamin assessment 3.